MedTrace Logo

Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy

NCT05285605 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-04-27

No results posted yet for this study

Summary

This study will entail provision of ulipristal acetate (UPA) for emergency contraception (EC) in the postpartum period for patients who have not chosen to initiate a highly effective form of contraception and study the use of EC overall as well as with regards to participants' perception of reproductive autonomy. The investigators hypothesize that providing an advance supply of EC will increase use and decrease barriers to use. Additionally, the investigators hypothesize that, with thorough EC counseling, participants will develop an increased knowledge base of EC. With increased use and knowledge, the investigators hypothesize that participants will experience greater reproductive autonomy over their contraceptive decisions.

Conditions

  • Contraception
  • Contraceptive Usage
  • Reproductive Issues

Interventions

DRUG

Ulipristal Acetate

Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse

Sponsors & Collaborators

Principal Investigators

  • Ashley M Turner, MD MSc · Northwestern University Feinberg School of Medicine

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-01
Completion
2024-01-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05285605 on ClinicalTrials.gov